Cvi Holdings, LLC Rezolute, Inc. Transaction History

Cvi Holdings, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.74 - $1.24 $92,350 - $154,749	-124,798 Reduced 25.9%	356,978 $353,000
Q3 2023 Nov 14, 2023	SELL	$1.32 - $2.1 $134,968 - $214,722	-102,249 Reduced 17.51%	481,776 $635,000
Q2 2023 Aug 11, 2023	SELL	$1.75 - $2.33 $88,389 - $117,683	-50,508 Reduced 7.96%	584,025 $1.16 Million
Q1 2023 May 16, 2023	SELL	$1.79 - $2.87 $133,322 - $213,763	-74,482 Reduced 10.5%	634,533 $1.22 Million
Q4 2022 Feb 14, 2023	SELL	$1.38 - $2.84 $201,434 - $414,546	-145,967 Reduced 17.07%	709,015 $1.47 Million
Q3 2022 Nov 14, 2022	SELL	$2.19 - $3.49 $110,750 - $176,492	-50,571 Reduced 5.58%	854,982 $2.34 Million
Q2 2022 Aug 15, 2022	BUY	$2.6 - $3.85 $2.35 Million - $3.49 Million	905,553 New	905,553 $2.93 Million

38.5M

1.6K

24.6K

Ticker RZLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,600
Market Cap $172M
Description
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...

Get notified when there are updates to the investment portfolio of Cvi Holdings, LLC, based on Form 13F filings with the SEC.

Stay updated on Cvi Holdings, LLC with notifications on news.